Eli Lilly does not do things by accident. When the company spent billions developing two GLP-1-based weight management medications — one an injectable dual-agonist (Zepbound) and one an oral single-agonist (Foundayo) — the strategy was always bigger than either product alone. Lilly built a weight management system: a clinically aggressive front-end for losing weight and a convenient, affordable back-end for keeping it off. Understanding this strategy helps you evaluate whether you are the right patient for this pathway.
Quick Answer
Lilly's two-product strategy pairs Zepbound for active weight loss with Foundayo for long-term maintenance. The logic is sound: patients need maximum efficacy when losing weight but maximum convenience and affordability when maintaining. Foundayo's oral format, lower cost, and sufficient-for-maintenance efficacy make it a natural step-down from Zepbound for patients who have already reached their goal. This is not just marketing — there are real clinical and practical reasons this pathway works.
Why Lilly Made Foundayo Oral
Orforglipron (Foundayo) is a non-peptide GLP-1 receptor agonist. Unlike semaglutide or tirzepatide, which are peptide-based molecules that get destroyed by stomach acid (requiring injection or special formulation), orforglipron was designed from the ground up as a small molecule that survives oral administration.
This was a deliberate strategic decision, not a scientific accident. Here is why oral matters for the maintenance use case:
Adherence Over Years, Not Months
The single biggest challenge in long-term weight management is not losing weight — it is staying on treatment long enough to keep it off. Data from GLP-1 discontinuation studies show that most patients regain 50–100% of lost weight within 12–24 months of stopping medication. This means effective weight management requires years of continuous treatment for most patients.
Weekly injections are tolerable for 6–12 months of active weight loss when motivation is high. They are less tolerable for 5, 10, or 20 years of maintenance. A daily pill that you take with breakfast and do not think about again is a fundamentally different adherence proposition than a weekly injection that requires refrigeration, needle handling, and injection site rotation.
Cost Structure for Long-Term Use
Injectable GLP-1 medications are expensive to manufacture, distribute, and administer. Cold chain logistics, specialized delivery devices, and healthcare system injection training all add cost. An oral tablet eliminates nearly all of this overhead. Lilly priced Foundayo lower than Zepbound in part because it can — the manufacturing and distribution economics of a pill are dramatically better than those of a biologic injection.
For patients, this translates to lower out-of-pocket costs. For the healthcare system, it means a more scalable solution. For Lilly, it means a product that can reach far more patients at a sustainable margin. For detailed cost comparisons, see our Foundayo cost and pricing guide.
Market Expansion
Many patients who would benefit from GLP-1 therapy never start because they are needle-averse. Surveys consistently show that 15–25% of potential GLP-1 candidates decline treatment specifically because it requires injections. An oral option removes this barrier entirely, expanding the addressable market for weight management pharmacotherapy.
The "Lose with Zepbound, Maintain with Foundayo" Playbook
Here is how the two-product strategy works in practice:
Phase 1: Active Weight Loss with Zepbound
Zepbound (tirzepatide) is the heavy hitter. Its dual GIP/GLP-1 mechanism delivers the most aggressive weight loss available in a single medication — up to 22.5% body weight reduction in clinical trials. During the active loss phase (typically 6–18 months), the patient tolerates weekly injections and higher costs because the results are dramatic and motivating.
Zepbound's role is to get the patient to goal weight as efficiently as possible. The dual-agonist mechanism provides powerful appetite suppression, improved insulin sensitivity, and metabolic benefits that accelerate weight loss beyond what GLP-1-only agents typically achieve.
Phase 2: Transition to Foundayo for Maintenance
Once the patient reaches their target weight, the clinical objective shifts from maximum efficacy to maximum sustainability. This is where Foundayo enters the picture.
The transition typically happens when:
- The patient has achieved 80–100% of their weight loss goal
- Weight has been stable for at least 4–8 weeks on Zepbound
- The patient is ready to prioritize convenience and cost over peak pharmacological intensity
The patient starts Foundayo at a low dose, titrates up over 4–8 weeks, and stabilizes on a maintenance dose. For a step-by-step guide, see our Zepbound to Foundayo switching guide.
Phase 3: Long-Term Maintenance
Foundayo becomes the indefinite maintenance medication. The patient takes a daily pill, sees their provider periodically for monitoring, and maintains their weight loss without the logistical burden of injectable therapy. The lower cost makes indefinite treatment more financially sustainable.
Clinical Data Supporting Maintenance Use
While no clinical trial has specifically studied the Zepbound → Foundayo transition pathway, the supporting evidence comes from several directions:
ATTAIN Trial Data
The ATTAIN clinical trial program demonstrated that orforglipron (Foundayo) produces approximately 10–12% body weight reduction in treatment-naive patients over 36–72 weeks. For maintenance purposes, the relevant data point is not peak weight loss but weight stability — the ability to prevent regain in patients who have already lost weight.
The weight loss curve in ATTAIN trials shows a plateau effect at higher doses, suggesting that orforglipron reaches a steady state that can sustain weight at a lower level. This plateau behavior is consistent with effective maintenance pharmacotherapy.
GLP-1 Maintenance Precedent
The broader GLP-1 literature supports the concept of using a less intensive agent for maintenance. Studies of semaglutide step-down protocols have shown that patients can maintain weight loss on lower doses than those required for initial loss. The principle — less pharmacological intensity is needed for maintenance than for active loss — is well-established.
Orforglipron's Pharmacological Profile
Orforglipron has several characteristics that make it well-suited for long-term maintenance:
- Consistent daily dosing produces stable drug levels (unlike weekly injections with peak-trough fluctuations)
- No food interaction requirements make adherence simpler than older oral GLP-1s like Rybelsus
- Non-peptide structure eliminates immunogenicity concerns that can arise with long-term peptide therapy
- GI side effect profile that tends to diminish over time, making long-term tolerance favorable
Zepbound vs Foundayo for Maintenance
| Factor | Zepbound (Maintenance) | Foundayo (Maintenance) |
|---|---|---|
| Efficacy for preventing regain | Strongest available (dual-agonist) | Sufficient for most maintenance patients |
| Administration | Weekly injection | Daily oral pill |
| Storage | Refrigeration required | Room temperature |
| Cost (self-pay) | $549+/month | $149–$299/month |
| Cost (savings card) | $25/month | $25/month |
| Daily friction | Low (weekly) | Minimal (daily pill) |
| Long-term adherence outlook | Good but injection fatigue possible | Excellent (pill convenience) |
| GIP pathway benefit | Yes | No |
| Travel convenience | Requires cold storage, needles | Pill bottle only |
For most maintenance patients, the right column wins on every practical measure except raw pharmacological power. The question is whether you need that extra power for maintenance — and for the majority, the answer is no. For a broader look at maintenance options across all GLP-1 medications, see our guide on the best GLP-1 for maintenance.
Who This Strategy Works Best For
The Zepbound → Foundayo pathway is most effective for patients who fit this profile:
- Achieved 15%+ body weight loss on Zepbound and are within 5–10 pounds of their goal
- Weight has been stable for 4+ weeks on their current Zepbound dose
- Primary diagnosis is obesity, not type 2 diabetes (the GIP component matters more for diabetes management)
- Cost-sensitive — either self-pay or concerned about long-term affordability
- Prefer oral medication for lifestyle, travel, or psychological reasons
- Committed to long-term pharmacotherapy — they understand they will likely need medication indefinitely and want the most sustainable option
Potential Concerns with This Approach
The strategy is not without risks and limitations:
The Efficacy Gap
Foundayo delivers approximately 10–12% body weight loss in treatment-naive patients. Zepbound delivers approximately 18–22% in similar populations. For maintenance, the relevant question is whether Foundayo provides enough pharmacological support to prevent regain — not whether it matches Zepbound's peak loss. Early data suggests it does for most patients, but a subset (~10–15%) may require the dual-agonist mechanism to maintain their loss.
The GIP Component Loss
For patients whose metabolic profile specifically benefits from GIP activation (particularly those with insulin resistance or dyslipidemia), losing the GIP component could result in measurable metabolic changes beyond weight. Monitoring lipid panels and glucose markers during the transition is important.
Insurance Complications
Switching medications can trigger new prior authorization requirements. Some insurance plans may question why a patient is changing from a medication that was working. Having clinical documentation of the maintenance rationale can smooth this process.
Not Everyone Can Switch Successfully
Some patients genuinely need the dual-agonist mechanism long-term. If you try Foundayo and experience meaningful weight regain (>5% over 3 months) or loss of metabolic control, the answer is to go back to Zepbound, not to push through on an insufficient medication.
The Long-Term Outlook
Lilly's two-product strategy is just the first version of what will become a common pattern across the pharmaceutical industry. The model — use the most powerful tool for active treatment, then step down to the most practical tool for maintenance — will expand as more oral GLP-1 medications enter the market.
Novo Nordisk is developing oral semaglutide for weight loss (with fasting requirements), which could compete directly with Foundayo in the maintenance space. Amgen, Pfizer, and others have oral GLP-1 programs in development. The competitive landscape will only improve the options available to patients over the next 2–5 years.
For Lilly specifically, the Zepbound + Foundayo combination represents a full lifecycle solution. It keeps patients within Lilly's product ecosystem from initial treatment through indefinite maintenance, which is good business strategy and, in this case, also good clinical strategy. The two products genuinely complement each other in a way that benefits patients.
Bottom Line
Lilly's "lose with Zepbound, maintain with Foundayo" strategy is commercially motivated but clinically sound. Patients who have achieved their weight loss goals on Zepbound can transition to Foundayo for long-term maintenance with reasonable confidence that the oral GLP-1 will provide sufficient support to prevent regain. The cost savings, convenience improvements, and adherence advantages of an oral maintenance option are real and meaningful.
The key is timing the switch appropriately — at or near goal weight, with stable weight trends — and monitoring the transition closely for the first 3 months. For patients who fit the profile, this pathway represents one of the most practical approaches to long-term weight management available in 2026.
Sources
- Eli Lilly and Company. Foundayo (orforglipron) Prescribing Information and Clinical Overview. 2026.
- Eli Lilly and Company. Zepbound (tirzepatide) Prescribing Information. 2025.
- ATTAIN Clinical Trial Program Results. Eli Lilly. Published 2024–2025.
- Wilding JPH, et al. "Weight regain and cardiometabolic effects after withdrawal of semaglutide." Diabetes, Obesity and Metabolism. 2022;24(8):1553-1564.
- Eli Lilly. "Foundayo Access and Pricing Strategy." Investor Day Presentation. 2026.
- Wharton S, et al. "Maintaining weight loss with GLP-1 receptor agonists: clinical evidence and practice considerations." Obesity Reviews. 2025;26(2):e13812.